Fine-tuning of ENA® gapmers as antisense oligonucleotides for sequence-specific inhibition

Oligonucleotides

Volumn 17, Issue 3, 2007, Pages 291-301

  Takagi Sato, Miho ^a   Tokuhiro, Shinya ^a   Kawaida, Reimi ^a   Koizumi, Makoto ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2' O 4' C ETHYLENE BRIDGED NUCLEIC ACID ANTISENSE GAPMER; ANTISENSE OLIGONUCLEOTIDE; MESSENGER RNA; OLIGONUCLEOTIDE; PEPTIDYLARGININE DEIMINASE 4; PROTEIN ARGININE DEIMINASE; RIBONUCLEASE H; RNA OLIGONUCLEOTIDE; UNCLASSIFIED DRUG;

ARTICLE; BASE PAIRING; CELL STRAIN 3T3; DNA SEQUENCE; DOWN REGULATION; ENZYME ACTIVITY; ESCHERICHIA COLI; GENE SEQUENCE; GENETIC ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REACTION ANALYSIS; SEQUENCE ANALYSIS;

ANIMALS; CELL LINE; HYDROLASES; MICE; OLIGONUCLEOTIDES, ANTISENSE; RIBONUCLEASE H; RNA, MESSENGER;

ESCHERICHIA COLI;

EID: 34648830157     PISSN: 15454576     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.2007.0078     Document Type: Article

References (42)

1. BAKER, B.F., LOT, S.S., CONDON, T.P., CHENG-FLOURNOY, S., LESNIK, E.A., SASMOR, H.M., and BENNETT, C.F. (1997). 2′-O-(2-Methoxy)ethyl- modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. J. Biol. Chem. 272, 11994-12000.
2. BRAASCH, D.A., LIU, Y., and COREY, D.R. (2002). Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design. Nucleic Acids Res. 30, 5160-5167.
3. BUTLER, M., McKAY, R.A., POPOFF, I.J., GAARDE, W.A., WITCHELL, D., MURRAY, S.F., DEAN, N.M., BHANOT, S., and MONIA, B.P. (2002). Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice, Diabetes 51, 1028-1034.
4. CROOKE, S.T., LEMONIDIS, K.M., NEILSON, L., GRIFFEY, R., LESNIK, E.A., and MONIA, B.P. (1995). Kinetic characteristics of Escherichia coli RNase H1: cleavage of various antisense oligonucleotide-RNA duplexes. Biochem. J. 312, 599-608.
5. CROOKE, R.M., GRAHAM, M.J., LEMONIDIS, K.M., WHIPPLE, C.P., KOO, S., and PERERA, R.J. (2005). An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J. Lipid Res. 46, 872-884.
6. DYKXHOORN, D.M., NOVINA, C.D., and SHARP, P.A. (2003). Killing the messenger: short RNAs that silence gene expression. Nat. Rev. Mol. Cell. Biol. 4, 457-467.
7. FRIEDEN, M., CHRISTENSEN, S.M., MIKKELSEN, N.D., ROSENBOHM, C., THRUE, C.A., WESTERGAARD, M., HANSEN, H.F., ORUM, H., and KOCH, T. (2003). Expanding the design horizon of antisense oligonucleotides with alpha-L-LNA. Nucleic Acids Res. 31, 6365-6372.
8. GILES, R.V., and TIDD, D.M. (1992). Increased specificity for antisense oligodeoxynucleotide targeting of RNA cleavage by RNase H using chimeric methylphosphonodiester/phosphodiester structures. Nucleic Acids Res. 20, 763-770.
9. HELENE C., and TOULME J.J. (1989). Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression. J.S. Cohen, ed. (MacMillan Press, London), pp 137-172.
10. HORIE, M., MORITA, K., KAWAKAMI, J., TSUTSUMI, S., ANDO, O., and KOIZUMI, M. (2006). Comparison between properties of 2′-O,4′-C- ethylene-bridged nucleic acid (ENA®) phosphorothioate oligonucleotides and N3′-P5′ thiophosphoramidate oligonucleotides, Nucleosides Nucleotides Nucleic Acids 25, 231-242.
11. INOUE, H., HAYASE, Y., IWAI, S., and OHTSUKA, E. (1987). Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and RNase H. FEBS Lett. 215, 327-330.
12. JEPSEN, J.S., PFUNDHELLER, H.M., and LYKKESFELDT, A.E. (2004). Downregulation of p21 (WAF1/CIP1) and estrogen receptor alpha in MCF-7 cells by antisense oligonucleotides containing locked nucleic acid (LNA). Oligonucleotides 14, 147-156.
13. KOIZUMI, M., TAKAGI-SATO, M., OKUYAMA, R., ARAKI, K., SUN, W., NAKAI, D., TSUTSUMI, S., and KAWAI, K. (2006). Direct comparison of in vivo antisense activity of ENA oligonucleotides targeting PTP1B mRNA with that of 2′-O-(2-methoxy)ethyl-modified oligonucleotides. Oligonucleotides 16, 253-262.
14. KOIZUMI, M. (2006) ENA oligonucleotides as therapeutics. Curr. Opin. Mol. Ther. 8, 144-149.
15. KOSHKIN, A.A., SINGH, S.K., NIELSEN, P., RAJWANSHI, V.K., KUMAR, R., MELDGAARD, M., OLSEN, C.E., and WENGEL, J. (1998). LNA (locked nucleic acids): synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition. Tetrahedron 54, 3607-3630.
16. KURRECK, J. (2003). Antisense technologies. Improvement through novel chemical modifications. Eur. J. Biochem. 270, 1628-1644.
17. KURRECK, J., WYSZKO, E., GILLEN, C., and ERDMANN, V.A. (2003). Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Res. 30, 1911-1918.
18. LARROUY, B.L., BLONSKI, C., BOIZIAU, C., STUER, M., MOREEAU, S., SHIRE D., and TOULME, J.-J. (1992) RNase H-mediated inhibition of translation by antisense oligodeoxyribonucleotides: use of backbone modification to improve specificity. Gene 121, 189-194.
19. LARROUY, B., BOIZIAU, C., SPROAT, B., and TOULME, J.-J. (1995). RNase H is responsible for the non-specific inhibition of in vitro translation by 2′-O-alkyl chimeric oligonucleotides: high affinity or selectivity, a dilemma to design antisense oligomers. Nucleic Acids Res. 23, 3434-3440.
20. LIMA, W.F., and CROOKE, S.T. (1997). Binding affinity and specificity of Escherichia coli RNase H1: impact on the kinetics of catalysis of antisense oligonucleotide-RNA hybrids. Biochemistry 36, 390-398.
21. LIMA, W., ROSE. J.B., NICHOLS, J.G., WU, H., MIGAWA, M.T., WYRZYKIEWICZ, T.K., SIWKOWSKI, A.M., and CROOKE, S.T. (2007a). Human RNase H1 discriminates between subtle variations in the structure of the heteroduplex substrate. Mol. Pharmacol. 71, 83-91.
22. LIMA, W., ROSE. J.B., NICHOLS, J.G., WU, H., MIGAWA, M.T., WYRZYKIEWICZ, T.K., VASQUEZ, G., SWAYZE, E.E., and CROOKE, S.T. (2007b). The positional influence of the helical geometry of the heteroduplex substrate on human RNase H1 catalysis. Mol. Pharmacol. 71, 73-82.
23. MONIA, B.P., LESNIK, E.A., GONZALEZ, C., LIMA, W.F., McGEE, D., GUINOSSO, C.J,, KAWASAKI, A.M., COOK, P.D., and FREIER, S.M. (1993). Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem. 268, 14514-14522.
24. MONIA, B.P., SIWKOWSKI, A.W., and BHANOT, S. (2006). Enhanced antisense oligonucleotides. WO2006/034348 (May 30, 2006).
25. MORITA, K., HASEGAWA, C., KANEKO, M., TSUTSUMI, S., SONE, J., ISHIKAWA, T., IMANISHI, T. and KOIZUMI, M. (2002) 2′-O,4′-C- Ethylene-bridged nucleic acids (ENA): highly nuclease-resistant and thermodynamically stable oligonucleotides for antisense drug. Bioorg. Med. Chem. Lett. 12, 73-76.
26. MORITA, K., TAKAGI, M., HASEGAWA, C., KANEKO, M., TSUTSUMI, S., SONE, J., ISHIKAWA, T., IMANISHI, T., and KOIZUMI, M (2003). Synthesis and properties of 2′-O,4′-C-ethylene-bridged nucleic acids (ENA) as effective antisense oligonucleotides. Bioorg. Med. Chem. 11, 2211-2226.
27. MORITA, K., YAMATE, K., KURAKATA, S., ABE, K., WATANABE, K., IMANISHI, T., and KOIZUMI, M. (2006). Inhibition of VEGF mRNA by 2′-O,4′-C- ethylenebridged nucleic acids (ENA) antisense oligonucleotides and their influence on off-target gene expressions. Nucleosides Nucleotides Nucleic Acids. 25, 503-521.
28. OBIKA, S., NANBU, D., HARI, Y., MORIO, K., IN, Y., ISHIDA, T., and IMANISHI, T. (1997). Synthesis of 2′-O,4′-C- methyleneuridine and -cytidine. Novel bicyclic nucleosides having a fixed C3′-endo sugar puckering. Tetrahedron Lett. 38, 8735-8738.
29. OBIKA, S., UNEDA, T., SUGIMOTO, T., NANBU, D., MINAMI, T., DOI, T., and IMANISHI, T. (2001). 2′-O,4′-C-Methylene bridged nucleic acid (2′,4′-BNA): synthesis and triplex-forming properties. Bioorg. Med. Chem. 9, 1001-1011.
30. ORUM, H. (2005). Engineering genomics. RNA antagonists - a new class of antisense drugs. IEEE Eng. Med. Biol. Mag. 24, 81-87.
31. SAZANI, P., GEMIGNANI, F., KANG, S.H., MAIER, M.A., MANOHARAN, M., PERSMARK, M., BORTNER, D., and KOLE, R. (2002). Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nat. Biotechnol. 20, 11228-11233.
32. SHEN, L.X., KANDIMALLA, E.R., and AGRAWAL, S. (1998). Impact of mixed-backbone oligonucleotides on target binding affinity and target cleaving specificity and selectivity by Escherichia coli RNase H. Bioorg. Med. Chem. 6, 1695-1705.
33. SLEDZ, C.A., HOLKO, M., De VEER, M.J., SILVERMAN, R.H., and WILLIAMS, B.R. (2003). Activation of the interferon system by short-interfering RNAs. Nat. Cell. Biol. 5, 834-839.
34. SURONO, A., Van KHANH, T., TAKESHIMA, Y., WADA, H., YAGI, M., TAKAGI, M., KOIZUMI, M., and MATSUO, M. (2004). Chimeric RNA/ethylene-bridged nucleic acids promote dystrophin expression in myocytes of duchenne muscular dystrophy by inducing skipping of the nonsense mutation-encoding exon. Hum. Gene. Ther. 15, 749-757.
35. SUZUKI, A., YAMADA, R., CHANG, X., TOKUHIRO, S., SAWADA, T., SUZUKI, M., NAGASAKI, M., NAKAYAMA-HAMADA, M., KAWAIDA, R., ONO, M., OHTSUKI, M., FURUKAWA, H., YOSHINO, S., YUKIOKA, M., TOHMA, S., MATSUBARA, T., WAKITANI, S., TESHIMA, R., NISHIOKA, Y., SERINE, A., IIDA, A., TAKAHASHI, A., TSUNODA, T., NAKAMURA, Y., and YAMAMOTO, K. (2003). Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat. Genet. 34, 395-402.
36. TAKAGI, M., MORITA, K., NAKAI, D., NAKAGOMI, R., TOKUI, T., and KOIZUMI, M. (2004). Enhancement of the inhibitory activity of oatp antisense oligonucleotides by incorporation of 2′-O,4′-C- ethylene-bridged nucleic acids (ENA) without a loss of subtype selectivity. Biochemistry 43, 4501-4510.
37. TAKAGI-SATO, M., TOKUHIRO, S., KAWAIDA, R., and KOIZUMI, M., (2006). Design of ENA gapmers as fine-tuning antisense oligonucleotides with sequence-specific inhibitory activity on mouse PADI4 mRNA expression. Nucleic Acids Symp. Ser. No. 50, 319-320.
38. WOOLF, T.M., MELTON, D.A., and JENNINGS, C.G. (1992). Specificity of antisense oligonucleotides in vivo. Proc. Natl. Acad. Sci. USA 89, 7305-7309.
39. WU, H., LIMA, W.F., and CROOKE, S.T. (1999). Properties of cloned and expressed human RNase H1. J. Biol. Chem. 274, 28270-28278.
40. YU, X.X., MURRAY, S.F., PANDEY, S.K., BOOTEN, S.L., BAO, D., SONG, X.Z., KELLY, S., CHEN, S., McKAY, R., MONIA, B.P., and BHANOT, S. (2005). Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice. Hepatology 42, 362-371.
41. ZHANG, H., COOK, J., NICKEL, J., YU, R., STECKER, K., MYERS, K., and DEAN, N.M. (2000). Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis. Nat. Biotechnol. 18, 862-867.
42. ZINKER, B.A., RONDINONE, C.M., TREVILLYAN, J.M., GUM, R.J., CLAMPIT, J.E., WARING, J.F., XIE, N., WILCOX, D., JACOBSON, P., FROST, L., KROEGER, P.E., REILLY, R.M., KOTERSKI, S., OPGENORTH, T.J., ULRICH, R.G., CROSBY, S., BUTLER, M., MURRAY, S.F., McKAY, R.A., BHANOT, S., MONIA, B.P., and JIROUSEK, M.R. (2002). PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proc. Natl. Acad. Sci. USA 99, 11357-11362.